Gsk (GSK) Cash & Equivalents (2009 - 2026)

Gsk (GSK) has 18 years of Cash & Equivalents data on file, last reported at $4.2 billion in Q2 2026.

• For the quarter ending Q2 2026, Cash & Equivalents fell 13.23% year-over-year to $4.2 billion; the trailing twelve-month figure through Jun 2026 stood at $4.2 billion (down 13.23% YoY), and the FY2025 full-year result was $4.5 billion, down 8.66% from the prior year.
• Cash & Equivalents was $4.2 billion for Q2 2026 at Gsk, down from $4.6 billion in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $8.1 billion in Q2 2022 to a low of $512.6 million in Q1 2022.
• A 5-year average of $4.3 billion and a median of $4.2 billion in 2022 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents sank 92.19% in 2022 and jumped 585.32% in 2023, its largest moves.
• Gsk's Cash & Equivalents stood at $4.4 billion in 2022, then slipped by 16.55% to $3.6 billion in 2023, then soared by 36.31% to $5.0 billion in 2024, then dropped by 9.03% to $4.5 billion in 2025, then dropped by 7.8% to $4.2 billion in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $4.2 billion in Q2 2026, $4.6 billion in Q1 2026, and $4.5 billion in Q4 2025.